The dual role of empagliflozin: Cardio renal protection in T2DM patients

Empagliflozin (Jardiance®) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective propert...

Full description

Saved in:
Bibliographic Details
Published in:Annals of medicine and surgery 2022-09, Vol.81, p.104555-104555, Article 104555
Main Authors: Shafiq, Aimen, Mahboob, Eman, Samad, Muhammad Ammar, Ur Rehman, Mohammad Hassam, Tharwani, Zoaib Habib
Format: Article
Language:English
Subjects:
Cardio protective
Empagliflozin
Reno protective
Short Communication
Side effects
Type 2 diabetes mellitus
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Empagliflozin (Jardiance®) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective properties its prime target are patients having CVD and CKD complicated by T2D. This review sheds light on mechanism of action of the drug and with the help of clinical outcomes establishes the use of empagliflozin in T2D patients. Although empagliflozin is a well-tolerated and easy to administer drug, it has some side effects and contraindications which are discussed in the article to help the reader weigh its beneficial effects against its adverse effect and understand its use in clinical medicine.
ISSN:2049-0801
2049-0801
DOI:10.1016/j.amsu.2022.104555